Literature DB >> 23590435

Role of microRNAs in mechanisms of glioblastoma resistance to radio- and chemotherapy.

Ph A Koshkin1, D A Chistiakov, V P Chekhonin.   

Abstract

Low-grade gliomas and multiform glioblastoma are characterized by highly pronounced anaplasia, malignization, proliferation, and invasiveness; moreover, they are highly resistant to chemo- and radiotherapy. The very low efficiency of traditional approaches in the treatment of patients with glioblastomas is due to the intensive invasive growth of the tumor resulting in deep infiltration of adjacent normal perivascular and nervous tissue and formation of areas of perineural infiltration differently remote from the tumor epicenter. MicroRNAs are key posttranscriptional regulators of gene activities, and their expression is markedly increased in tumors, in particular in gliomas. MicroRNAs have been shown to promote the growth, proliferation, migration, and survival of tumor stem and non-stem cells. However, a population of microRNA possessing antitumor effects is also detected in gliomas. As a rule, the expression of antitumor microRNAs is suppressed in tumors. In this review, we consider microRNAs, their influence on radio- and chemoresistance of gliomas, and prospects for their use as specific agents in targeted therapy of gliomas. The pool of these microRNAs has distinct therapeutic value, because on use in combined therapy it can decrease the resistance of glioma tumor stem cells to existing pharmaceuticals and improve the efficiency of radio- and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23590435     DOI: 10.1134/S0006297913040019

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  8 in total

1.  MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response.

Authors:  Andrej Besse; Jiri Sana; Radek Lakomy; Leos Kren; Pavel Fadrus; Martin Smrcka; Marketa Hermanova; Radim Jancalek; Stefan Reguli; Radim Lipina; Marek Svoboda; Pavel Slampa; Ondrej Slaby
Journal:  Tumour Biol       Date:  2015-12-21

2.  MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.

Authors:  Jian Wang; Yongli Li; Chuanlu Jiang
Journal:  J Mol Neurosci       Date:  2014-10-30       Impact factor: 3.444

3.  Predictive and Prognostic Roles of Abnormal Expression of Tissue miR-125b, miR-221, and miR-222 in Glioma.

Authors:  Xinxing Li; Jihui Zheng; Liangyu Chen; Hongyu Diao; Yunhui Liu
Journal:  Mol Neurobiol       Date:  2014-12-11       Impact factor: 5.590

4.  MicroRNA-96 Regulates Apoptosis by Targeting PDCD4 in Human Glioma Cells.

Authors:  Qing-Qing Ma; Jian-Ting Huang; Yun-Gang Xiong; Xiao-Yan Yang; Ran Han; Wang-Wen Zhu
Journal:  Technol Cancer Res Treat       Date:  2016-07-07

5.  NOS2 expression in glioma cell lines and glioma primary cell cultures: correlation with neurosphere generation and SOX-2 expression.

Authors:  Paola Palumbo; Gianfranca Miconi; Benedetta Cinque; Francesca Lombardi; Cristina La Torre; Soheila Raysi Dehcordi; Renato Galzio; Annamaria Cimini; Antonio Giordano; Maria Grazia Cifone
Journal:  Oncotarget       Date:  2017-04-11

6.  MiRNA-7 Replacement Effect on Proliferation and Tarceva-Sensitivity in U373-MG Cell Line.

Authors:  Vahab Alamdari-Palangi; Zahra Karami; Hadi Karami; Maryam Baazm
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

7.  Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.

Authors:  Jia Shi; Xuchen Dong; Wei Han; Peng Zhou; Liang Liu; Haiyang Wang; Qianqian Jiang; Haoran Li; Shan Cheng; Suwen Li; Jiaqi Yuan; Zhiyuan Qian; Jun Dong
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

8.  MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways.

Authors:  Yilong Yao; Yixue Xue; Jun Ma; Chao Shang; Ping Wang; Libo Liu; Wenjing Liu; Zhen Li; Shengtao Qu; Zhiqing Li; Yunhui Liu
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.